Immunoblotting in Detection of Tumor-Associated Antigens in Esophageal Squamous Cell Carcinoma

  • Farhadul Islam
  • Vinod Gopalan
  • Alfred K. LamEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 2129)


Tumor-associated antigens (TAAs) can be used as cancer markers and as signposts of therapeutic targets since their inimitable expression in cancer or significant overexpression in esophageal squamous cell carcinoma (ESCC) correlates with the initiation and progression of the diseases. Immunoblotting, also known as Western blotting or protein blotting, is a core technique in cell and molecular biology to detect proteins and glycoproteins. The technique allows detection of TAAs from complex protein samples such as in serum, aspirate, or solid tumor homogenate. In the process, proteins are separated according to the molecular weight. They were visualized within a gel matrix and then transferred to a supporting membrane. Finally, they are probed for binding with corresponding antibodies and identified the target proteins. Herein, we describe the Western blots analysis to detect protein or glycoprotein in samples from patients with esophageal squamous cell carcinoma (ESCC) or cells derived from ESCC.

Key words

Tumor-associated antigen Immunoblots Western blots Protein blots ESCC 


  1. 1.
    Harao M, Mittendorf EA, Radvanyi LG (2015) Peptide-based vaccination and induction of CD8+ T-cell responses against tumor antigens in breast cancer. BioDrugs 29:15–30CrossRefGoogle Scholar
  2. 2.
    Gao HJ, Yue ZG, Zheng M, Zheng ZX (2012) Identification and expression of a tumor-associated antigen in esophageal squamous cell carcinoma. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 34:244–248PubMedGoogle Scholar
  3. 3.
    Lee SY, Jeoung D (2007) The reverse proteomics for identification of tumor antigens. J Microbiol Biotechnol 17:879–890PubMedGoogle Scholar
  4. 4.
    Fernandez MF, Tang N, Alansari H, Karvonen RL, Tomkiel JE (2005) Improved approach to identify cancer-associated autoantigens. Autoimmun Rev 4:230–235CrossRefGoogle Scholar
  5. 5.
    Liu CC, Yang H, Zhang R, Zhao JJ, Hao DJ (2017) Tumour-associated antigens and their anti-cancer applications. Eur J Cancer Care 26:e12446CrossRefGoogle Scholar
  6. 6.
    Zhang JY, Looi KS, Tan EM (2009) Identification of tumor-associated antigens as diagnostic and predictive biomarkers in cancer. Methods Mol Biol 520:1–10CrossRefGoogle Scholar
  7. 7.
    Xu WW, Li B, Lam AK, Tsao SW, Law SY, Chan KW, Yuan QJ, Cheung AL (2015) Targeting VEGFR1- and VEGFR2-expressing non-tumor cells is essential for esophageal cancer therapy. Oncotarget 6:1790–1805PubMedGoogle Scholar
  8. 8.
    Islam F, Gopalan V, Law S, Tang JC, Lam AK (2019) FAM134B promotes esophageal squamous cell carcinoma in vitro and its correlations with clinicopathologic features. Hum Pathol 87:1–10CrossRefGoogle Scholar
  9. 9.
    Yu VZ, Wong VC, Dai W, Ko JM, Lam AK, Chan KW, Samant RS, Lung HL, Shuen WH, Law S, Chan YP, Lee NP, Tong DK, Law TT, Lee VH, Lung ML (2015) Nuclear localization of DNAJB6 is associated with survival of patients with esophageal cancer and reduces akt signaling and proliferation of cancer cells. Gastroenterology 149:1825–1836.e5CrossRefGoogle Scholar
  10. 10.
    Chai AW, Cheung AK, Dai W, Ko JM, Ip JC, Chan KW, Kwong DL, Ng WT, Lee AW, Ngan RK, Yau CC, Tung SY, Lee VH, Lam AK, Pillai S, Law S, Lung ML (2016) Metastasis-suppressing NID2, an epigenetically-silenced gene, in the pathogenesis of nasopharyngeal carcinoma and esophageal squamous cell carcinoma. Oncotarget 7:78859–78871CrossRefGoogle Scholar
  11. 11.
    Li B, Xu WW, Lam AKY, Wang Y, Hu HF, Guan XY, Qin YR, Saremi N, Tsao SW, He QY, Cheung ALM (2017) Significance of PI3K/AKT signaling pathway in metastasis of esophageal squamous cell carcinoma and its potential as a target for anti-metastasis therapy. Oncotarget 8:38755–38766PubMedPubMedCentralGoogle Scholar
  12. 12.
    Gopalan V, Islam F, Pillai S, Tang JC, Tong DK, Law S, Chan KW, Lam AK (2016) Overexpression of microRNA-1288 in oesophageal squamous cell carcinoma. Exp Cell Res 348:146–154CrossRefGoogle Scholar
  13. 13.
    Islam F, Gopalan V, Law S, Tang JC, Chan KW, Lam AK (2017) MiR-498 in esophageal squamous cell carcinoma: clinicopathological impacts and functional interactions. Hum Pathol 62:141–151CrossRefGoogle Scholar
  14. 14.
    Ng HY, Li J, Tao L, Lam AK, Chan KW, Ko JMY, Yu VZ, Wong M, Li B, Lung ML (2018) Chemotherapeutic treatments increase PD-L1 expression in esophageal squamous cell carcinoma through EGFR/ERK activation. Transl Oncol 11:1323–1333CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  • Farhadul Islam
    • 1
    • 2
  • Vinod Gopalan
    • 1
  • Alfred K. Lam
    • 3
    Email author
  1. 1.Cancer Molecular Pathology of School of MedicineGriffith UniversityGold CoastAustralia
  2. 2.Department of Biochemistry and Molecular BiologyUniversity of RajshahiRajshahiBangladesh
  3. 3.Cancer Molecular Pathology, School of MedicineGriffith UniversityGold CoastAustralia

Personalised recommendations